Tuberculosis - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for tuberculosis including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development pipeline for tuberculosis

Tuberculosis is a disease caused by a bacterium called Mycobacterium Tuberculosis. This bacterium is present in the air and spreads from one person to another. It usually affects the lungs and can also target other body parts, including the spine, brain, and kidneys. According to the Centers for Disease Control and Prevention (CDC), 10.4 million people worldwide became sick with TB in 2016. Furthermore, 1.7 million TB-related deaths were reported worldwide. As per NIH, the incidence rate worldwide was 122 cases per 100,000 population in 2012. The prevalence of tuberculosis cases were the highest from the Western Pacific, Africa, Eastern Mediterranean region, Europe, and the Americas. As a result, this has encouraged market vendors to form collaborations with various non-profit organizations, such as The TB Alliance and Aeras, for the treatment of tuberculosis. Drug developing companies provide funding and help to initiate the research and development process by providing a dedicated R&D team. As a result, with the increasing incidences of tuberculosis, the drug development for tuberculosis will be promoted significantly during the predicted period.

According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for tuberculosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of tuberculosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Abera Bioscience
• Archivel Farma
• AstraZeneca
• EyeGene
• GlaxoSmithKline

Therapeutic assessment of the drug development pipeline for tuberculosis by route of administration

• Oral
• Intradermal
• Intramuscular
• Subcutaneous

The oral route of administration (ROA) involves the application of the drug directly through the mouth, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for tuberculosis by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for tuberculosis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for tuberculosis?
• What are the companies that are currently involved in the development of drug molecules for tuberculosis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.